89Zr-labeled NY008 PET Imaging in Patients
NCT05655676 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2022-12-19
Summary
This is a single arm study to evaluate the safety and biodistribution of 89Zr-labeled NY008 PET Imaging in patients with multiple myeloma
Conditions
Interventions
- DRUG
-
89Zr-NY008
Patients will receive a tracer (5-10mg, IV) dose of 89Zr (2-3mCi) labelled NY008
Sponsors & Collaborators
-
Affiliated Hospital of Jiangnan University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-05-25
- Primary Completion
- 2023-05-31
- Completion
- 2023-05-31
Countries
- China
Study Locations
More Related Trials
-
Comparison Between FDG-PET and MRI for the Assessment of Response to Intensive Chemotherapy in Multiple Myeloma Patients.
NCT00200668 ·Status: TERMINATED ·Phase: NA
-
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
NCT05892393 ·Status: RECRUITING ·Phase: PHASE1
-
A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma
NCT05448404 ·Status: UNKNOWN ·Phase: NA
-
Safety Study of 89Zr-Anti-CLDN18.2 mAbs PET Imaging in Patients With CLDN18.2 Positive Solid Tumors
NCT04989010 ·Status: UNKNOWN ·Phase: NA
-
A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.
NCT07319897 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Imaging in MGUS, SMM and MM
NCT01237054 ·Status: COMPLETED ·Phase: PHASE2
-
PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)
NCT06871176 ·Status: RECRUITING ·Phase: NA
-
PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma
NCT05662540 ·Status: RECRUITING ·Phase: NA
-
⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors
NCT03802123 ·Status: COMPLETED ·Phase: PHASE2
-
⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma
NCT03107663 ·Status: COMPLETED ·Phase: PHASE1
-
68Ga-NYM096 PET/CT in Various Kinds of Cancer
NCT07144748 ·Status: RECRUITING ·Phase: NA
-
Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple Myeloma
NCT06659276 ·Status: RECRUITING
-
68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma
NCT05364177 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma
NCT04561492 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
CD70-targeted immunoPET Imaging of Malignant Cancers
NCT06852638 ·Status: RECRUITING ·Phase: PHASE2
-
PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy
NCT00019565 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Whole Body Examination by MRI Integrating the "Zero Time Eco" Sequence (ZTE, Pseudo-CT) for the Detection of Bone Lesions in Multiple Myeloma: Comparison With Pet / CT and Whole Body Scanner
NCT05381077 ·Status: UNKNOWN ·Phase: NA
-
Efficacy of 68Ga-Pentixafor PET/MR in Detecting Non-Hodgkin Lymphoma and Multiple Myeloma Lesions
NCT06720207 ·Status: NOT_YET_RECRUITING
-
First Human Trial of Targeting MDM2/MDMX PET Imaging
NCT06443762 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma
NCT05681234 ·Status: COMPLETED ·Phase: NA
-
89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma
NCT01859234 ·Status: UNKNOWN ·Phase: NA
-
68Ga-N188 PET/CT Imaging in Malignancy
NCT05593107 ·Status: RECRUITING ·Phase: NA
-
CD8 PET Imaging in Metastatic Solid Tumours
NCT06534190 ·Status: RECRUITING ·Phase: PHASE2
-
PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations
NCT01089998 ·Status: COMPLETED ·Phase: PHASE1
-
PET Tracer Based FDG Signal for Predicting Prognosis in Acute Myeloid Leukemia
NCT05919199 ·Status: UNKNOWN